HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.

Abstract
Pharmacologic options for patients with castration-resistant prostate cancer are limited. It has been suggested that targeting intracellular molecules, which have been altered during neoplastic development, may slow tumor growth. Therefore, the growth-blocking potential of the histone deacetylase-inhibitor LBH589 and the multiple tyrosine kinase-inhibitor TKI258, applied alone or in combination, was investigated in a panel of prostate cancer cell lines. PC-3, DU-145 or LNCaP cells were treated with various concentrations of LBH589 and/or TKI258. Tumor cell growth, cell cycle regulating proteins, HDAC3- and HDAC4-expression and histone H3 and H4 acetylation were then evaluated by MTT assay and Western blotting. LBH589 dose-dependently blocked prostate cancer cell growth. In contrast, TKI258 did not down-regulate tumor cell growth up to a 1,000 nM dosage. LBH589 elevated histone H3 and H4 acetylation. The cell cycle regulators cyclin B, cyclin D1, cdk1 and cdk4 were down-regulated in PC-3, whereas the suppressor proteins p21 and p27 were up-regulated in LNCaP by LBH589. TKI258 up-regulated p27 in PC-3 or p21 in LNCaP and additionally elevated cyclin B, cyclin D1, cdk1 and cdk4 in both cell lines. Presumably, the increase in cyclin and cdk caused by TKI258 counteracts the benefit of p21 or p27 up-regulation, resulting in TKI258 non-responsiveness. The LBH589/TKI258-combination was not superior to the LBH589 single-drug use in terms of growth reduction. Obviously, TKI258 did not enhance the sensitivity of prostate cancer cells towards an HDAC based regimen. Therefore, the LBH589/TKI258-combination probably does not provide an optimum strategy in fighting advanced prostate cancer.
AuthorsStefan Vallo, Jens Mani, Matthias Stastny, Jasmina Makarević, Eva Juengel, Igor Tsaur, Georg Bartsch, Axel Haferkamp, Roman A Blaheta
JournalInvestigational new drugs (Invest New Drugs) Vol. 31 Issue 2 Pg. 265-72 (Apr 2013) ISSN: 1573-0646 [Electronic] United States
PMID22801803 (Publication Type: Journal Article)
Chemical References
  • 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
  • Benzimidazoles
  • Histone Deacetylase Inhibitors
  • Histones
  • Hydroxamic Acids
  • Indoles
  • Quinolones
  • Panobinostat
  • Receptor Protein-Tyrosine Kinases
  • Histone Deacetylases
Topics
  • Acetylation (drug effects)
  • Apoptosis (drug effects)
  • Benzimidazoles (pharmacology)
  • Blotting, Western
  • Cell Proliferation (drug effects)
  • Drug Therapy, Combination
  • Histone Deacetylase Inhibitors (pharmacology)
  • Histone Deacetylases (chemistry)
  • Histones (metabolism)
  • Humans
  • Hydroxamic Acids (pharmacology)
  • Indoles (pharmacology)
  • Male
  • Panobinostat
  • Prostatic Neoplasms (drug therapy, metabolism, pathology)
  • Quinolones (pharmacology)
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: